Korean J Gastroenterol.  2021 May;77(5):231-240. 10.4166/kjg.2021.077.

Treatment of Inflammatory Bowel Disease in Elderly Patients – What Are Different and What Should We Know?

• Na SY

• KMID: 2516040
• DOI: http://doi.org/10.4166/kjg.2021.077

Abstract

As the incidence of inflammatory bowel disease (IBD) are increasing with an ageing population, the incidence and prevalence of IBD in the elderly continue to increase. Older IBD patients can be classified into two groups; elderly-onset IBD patients and elderly IBD patients who were diagnosed at a young age and transitioning into advanced age. Clinicians must consider elderly-onset specific phenotypes or prognosis and age-related concerns in the treatment of elderly IBD patients. There is a paucity of evidence whether there is a different disease process when IBD occurs in older age yet. Clinicians may expect similar therapeutic effects in older and younger patients in drug selection, but since older patients are often excluded from clinical trials, evidence to support this assumption is currently lacking. Also, the risk of side effects may be higher in elderly patients. Therefore, when making management decisions in the elderly, clinicians should assess an individual’s frailty rather than only considering an individual’s chronological and biological age. Knowing specific requirements for managing older IBD patients may help to make an appropriate therapeutic strategy for this patient group.

Keyword

Inflammatory bowel diseases; Crohn disease; Colitis; ulcerative; Aged

Reference

1. Ng SC, Shi HY, Hamidi N, et al. 2017; Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 390:2769–2778. DOI: 10.1016/S0140-6736(17)32448-0.

2. Park SH, Kim YJ, Rhee KH, et al. 2019; A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986-2015. J Crohns Colitis. 13:1410–1417. DOI: 10.1093/ecco-jcc/jjz081. PMID: 30989166.

3. Coward S, Clement F, Benchimol EI, et al. 2019; Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology. 156:1345–1353. e4. DOI: 10.1053/j.gastro.2019.01.002. PMID: 30639677.

4. Yang SK. 2017; How does the epidemiology of inflammatory bowel disease differ between east and west? Inflamm Intest Dis. 2:95–101. DOI: 10.1159/000454712. PMID: 30018960. PMCID: PMC5988201.

5. Taleban S, Colombel JF, Mohler MJ, Fain MJ. 2015; Inflammatory bowel disease and the elderly: a review. J Crohns Colitis. 9:507–515. DOI: 10.1093/ecco-jcc/jjv059. PMID: 25870198.

6. Jeuring SF, van den Heuvel TR, Zeegers MP, et al. 2016; Epidemiology and long-term outcome of inflammatory bowel disease diagnosed at elderly age-an increasing distinct entity? Inflamm Bowel Dis. 22:1425–1434. DOI: 10.1097/MIB.0000000000000738. PMID: 26933752.

7. Nguyen GC, Sheng L, Benchimol EI. 2015; Health care utilization in elderly onset inflammatory bowel disease: a population-based study. Inflamm Bowel Dis. 21:777–782. DOI: 10.1097/MIB.0000000000000306. PMID: 25738376.

8. 2021. Feb. 18. Statistics of national diseases of interest. [Internet]. Health Insurance Review & Assessment Service;Wonju: Available from http://opendata.hira.or.kr/op/opc/olapMfrnIntrsIlnsInfo.do#none. cited 2021 Apr 30.

9. Song EM, Kim N, Lee SH, et al. 2018; Clinical characteristics and long-term prognosis of elderly-onset Crohn's disease. Scand J Gastroenterol. 53:417–425. DOI: 10.1080/00365521.2018.1437927. PMID: 29457917.

10. Charpentier C, Salleron J, Savoye G, et al. 2014; Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 63:423–432. DOI: 10.1136/gutjnl-2012-303864. PMID: 23408350.

11. Harper PC, McAuliffe TL, Beeken WL. 1986; Crohn's disease in the elderly. A statistical comparison with younger patients matched for sex and duration of disease. Arch Intern Med. 146:753–755. DOI: 10.1001/archinte.1986.00360160189025. PMID: 3963958.

12. Triantafillidis JK, Emmanouilidis A, Nicolakis D, Ifantis T, Cheracakis P, Merikas EG. 2000; Crohn's disease in the elderly: clinical features and long-term outcome of 19 Greek patients. Dig Liver Dis. 32:498–503. DOI: 10.1016/S1590-8658(00)80007-9.

13. Riegler G, Tartaglione MT, Carratú R, et al. 2000; Age-related clinical severity at diagnosis in 1705 patients with ulcerative colitis: a study by GISC (Italian Colon-Rectum Study Group). Dig Dis Sci. 45:462–465. DOI: 10.1023/A:1005424603085. PMID: 10749318.

14. Park SH, Jeong SK, Lee JH, et al. 2021; Jan. 19. Clinical characteristics and long-term prognosis of elderly-onset ulcerative colitis in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea. Gut Liver. [Epub ahead of print]. DOI: 10.5009/gnl20289.

15. Regueiro M, Kip KE, Cheung O, Hegazi RA, Plevy S. 2005; Cigarette smoking and age at diagnosis of inflammatory bowel disease. Inflamm Bowel Dis. 11:42–47. DOI: 10.1097/00054725-200501000-00006. PMID: 15674112.

16. Lakatos PL, David G, Pandur T, et al. 2011; IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. J Crohns Colitis. 5:5–13. DOI: 10.1016/j.crohns.2010.08.004. PMID: 21272797.

17. Hwang SW, Kim JH, Im JP, et al. 2017; Influence of age at diagnosis on the clinical characteristics of Crohn's disease in Korea: results from the CONNECT study. J Gastroenterol Hepatol. 32:1716–1722. DOI: 10.1111/jgh.13775. PMID: 28251684.

18. Ananthakrishnan AN, Shi HY, Tang W, et al. 2016; Systematic review and meta-analysis: phenotype and clinical outcomes of older-onset inflammatory bowel disease. J Crohns Colitis. 10:1224–1236. DOI: 10.1093/ecco-jcc/jjw054. PMID: 26928965. PMCID: PMC6082591.

19. Heresbach D, Alexandre JL, Bretagne JF, et al. 2004; Crohn's disease in the over-60 age group: a population based study. Eur J Gastroenterol Hepatol. 16:657–664. DOI: 10.1097/01.meg.0000108337.41221.08. PMID: 15201578.

20. Lamb CA, Kennedy NA, Raine T, et al. 2019; British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 68(Suppl 3):s1–s106.

21. Gisbert JP, Marín AC, Chaparro M. 2015; Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther. 42:391–405. DOI: 10.1111/apt.13276. PMID: 26075832.

22. Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. 2020; Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 8:CD000543. DOI: 10.1002/14651858.CD000543.pub5. PMID: 32786164.

23. Kim SB, Kim KO, Jang BI, et al. 2016; Patients' beliefs and attitudes about their treatment for inflammatory bowel disease in Korea. J Gastroenterol Hepatol. 31:575–580. DOI: 10.1111/jgh.13155. PMID: 26313162.

24. Heap GA, So K, Weedon M, et al. 2016; Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease. J Crohns Colitis. 10:149–158. DOI: 10.1093/ecco-jcc/jjv219. PMID: 26619893.

25. Ananthakrishnan AN, McGinley EL, Binion DG. 2009; Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. 15:182–189. DOI: 10.1002/ibd.20628. PMID: 18668678.

26. Löfberg R, Danielsson A, Suhr O, et al. 1996; Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology. 110:1713–1718. DOI: 10.1053/gast.1996.v110.pm8964395. PMID: 8964395.

27. Schoon EJ, Bollani S, Mills PR, et al. 2005; Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol. 3:113–121. DOI: 10.1016/S1542-3565(04)00662-7.

28. Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH. 2015; Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. (10):CD007698. DOI: 10.1002/14651858.CD007698.pub3. PMID: 26497719.

29. Bar-Meir S, Chowers Y, Lavy A, et al. 1998; Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology. 115:835–840. DOI: 10.1016/S0016-5085(98)70254-9.

30. Van Assche G, Manguso F, Zibellini M, et al. 2015; Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study. Am J Gastroenterol. 110:708–715. DOI: 10.1038/ajg.2015.114. PMID: 25869389.

31. Campieri M, Adamo S, Valpiani D, et al. 2003; Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther. 17:1471–1480. DOI: 10.1046/j.1365-2036.2003.01609.x. PMID: 12823149.

32. Chaparro M, Ordás I, Cabré E, et al. 2013; Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis. 19:1404–1410. DOI: 10.1097/MIB.0b013e318281f28f. PMID: 23665964.

33. Beaugerie L, Brousse N, Bouvier AM, et al. 2009; Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 374:1617–1625. DOI: 10.1016/S0140-6736(09)61302-7.

34. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. 2011; Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 141:1621–28. e285. DOI: 10.1053/j.gastro.2011.06.050. PMID: 21708105.

35. Lemaitre M, Kirchgesner J, Rudnichi A, et al. 2017; Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 318:1679–1686. DOI: 10.1001/jama.2017.16071. PMID: 29114832. PMCID: PMC5818785.

36. Lu MJ, Qiu XY, Mao XQ, Li XT, Zhang HJ. 2018; Systematic review with meta-analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 47:318–331. DOI: 10.1111/apt.14436. PMID: 29205426.

37. Herfarth HH, Kappelman MD, Long MD, Isaacs KL. 2016; Use of methotrexate in the treatment of inflammatory bowel diseases. Inflamm Bowel Dis. 22:224–233. DOI: 10.1097/MIB.0000000000000589. PMID: 26457382. PMCID: PMC4679484.

38. Mañosa M, Calafat M, de Francisco R, et al. 2018; Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study. Aliment Pharmacol Ther. 47:605–614. DOI: 10.1111/apt.14494. PMID: 29369387.

39. Calafat M, Mañosa M, Cañete F, et al. 2019; Increased risk of thiopurine-related adverse events in elderly patients with IBD. Aliment Pharmacol Ther. 50:780–788. DOI: 10.1111/apt.15458. PMID: 31429097.

40. Porcari S, Viola A, Orlando A, et al. 2020; Persistence on anti-tumour necrosis factor therapy in older patients with inflammatory bowel disease compared with younger patients: data from the sicilian network for inflammatory bowel diseases (SN-IBD). Drugs Aging. 37:383–392. DOI: 10.1007/s40266-020-00744-3. PMID: 32016824.

41. Lobatón T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. 2015; Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 42:441–451. DOI: 10.1111/apt.13294. PMID: 26104047.

42. Cheng D, Cushing KC, Cai T, Ananthakrishnan AN. 2021; Safety and efficacy of tumor necrosis factor antagonists in older patients with ulcerative colitis: patient-level pooled analysis of data from randomized trials. Clin Gastroenterol Hepatol. 19:939–946. e4. DOI: 10.1016/j.cgh.2020.04.070. PMID: 32371165.

43. de Jong ME, Smits LJT, van Ruijven B, et al. 2020; Increased Discontinuation rates of anti-TNF therapy in elderly inflammatory bowel disease patients. J Crohns Colitis. 14:888–895. DOI: 10.1093/ecco-jcc/jjaa012. PMID: 31974546.

44. Borren NZ, Ananthakrishnan AN. 2019; Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 17:1736–1743. e4. DOI: 10.1016/j.cgh.2018.12.032. PMID: 30616024. PMCID: PMC6609492.

45. Desai A, Zator ZA, de Silva P, et al. 2013; Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 19:309–315. DOI: 10.1002/ibd.23026. PMID: 22605668. PMCID: PMC4345352.

46. Singh S, Stitt LW, Zou G, et al. 2019; Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. Aliment Pharmacol Ther. 49:1188–1194. DOI: 10.1111/apt.15214. PMID: 30891808. PMCID: PMC6461484.

47. Feagan BG, Rutgeerts P, Sands BE, et al. 2013; Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 369:699–710. DOI: 10.1056/NEJMoa1215734. PMID: 23964932.

48. Sandborn WJ, Feagan BG, Rutgeerts P, et al. 2013; Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 369:711–721. DOI: 10.1056/NEJMoa1215739. PMID: 23964933.

49. Colombel JF, Sands BE, Rutgeerts P, et al. 2017; The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 66:839–851. DOI: 10.1136/gutjnl-2015-311079. PMID: 26893500. PMCID: PMC5531223.

50. Sands BE, Sandborn WJ, Panaccione R, et al. 2019; Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 381:1201–1214. DOI: 10.1056/NEJMoa1900750. PMID: 31553833.

51. Feagan BG, Sandborn WJ, Gasink C, et al. 2016; Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 375:1946–1960. DOI: 10.1056/NEJMoa1602773. PMID: 27959607.

52. Sandborn WJ, Rutgeerts P, Gasink C, et al. 2018; Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 48:65–77. DOI: 10.1111/apt.14794. PMID: 29797519. PMCID: PMC6032827.

53. Papp KA, Griffiths CE, Gordon K, et al. 2013; Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 168:844–854. DOI: 10.1111/bjd.12214. PMID: 23301632.

54. Menter A, Papp KA, Gooderham M, et al. 2016; Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis longitudinal assessment and registry (PSOLAR). J Eur Acad Dermatol Venereol. 30:1148–1158. DOI: 10.1111/jdv.13611. PMID: 27027388. PMCID: PMC5071685.

55. Papp K, Gottlieb AB, Naldi L, et al. 2015; Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 14:706–714.

56. Curtis JR, Schulze-Koops H, Takiya L, et al. 2017; Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. Clin Exp Rheumatol. 35:390–400.

57. Desai RJ, Pawar A, Khosrow-Khavar F, Weinblatt ME, Kim SC. 2021; Mar. 22. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohortstudy. Rheumatology (Oxford). [Epub ahead of print]. DOI: 10.1093/rheumatology/keab294. PMID: 33752237.

58. Mijac DD, Janković GL, Jorga J, Krstić MN. 2010; Nutritional status in patients with active inflammatory bowel disease: prevalence of malnutrition and methods for routine nutritional assessment. Eur J Intern Med. 21:315–319. DOI: 10.1016/j.ejim.2010.04.012. PMID: 20603043.

59. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. 2005; Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 293:2257–2264. DOI: 10.1001/jama.293.18.2257. PMID: 15886381.

60. The Korean Society of Infectious Diseases. 2019. Vaccinations for adults. 3rd ed. KOONJA Publishing Inc.;Paju:

61. Khan N, Vallarino C, Lissoos T, Darr U, Luo M. 2017; Risk of malignancy in a nationwide cohort of elderly inflammatory bowel disease patients. Drugs Aging. 34:859–868. DOI: 10.1007/s40266-017-0498-y. PMID: 29170864. PMCID: PMC5705754.

62. Lakatos L, Mester G, Erdelyi Z, et al. 2006; Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis. 12:205–211. DOI: 10.1097/01.MIB.0000217770.21261.ce. PMID: 16534422.

63. Beaugerie L, Svrcek M, Seksik P, et al. 2013; Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 145:166–175. e8. DOI: 10.1053/j.gastro.2013.03.044. PMID: 23541909.

64. Hou JK, Feagins LA, Waljee AK. 2016; Characteristics and behavior of elderly-onset inflammatory bowel disease: a multi-center US study. Inflamm Bowel Dis. 22:2200–2205. DOI: 10.1097/MIB.0000000000000849. PMID: 27482973.

65. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. 2004; Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol. 2:1088–1095. DOI: 10.1016/S1542-3565(04)00543-9.

66. Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B. 2013; Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 19:789–799. DOI: 10.1097/MIB.0b013e31828029c0. PMID: 23448792.

67. Shi HY, Chan FK, Leung WK, et al. 2016; Natural history of elderly-onset ulcerative colitis: results from a territory-wide inflammatory bowel disease registry. J Crohns Colitis. 10:176–185. DOI: 10.1093/ecco-jcc/jjv194. PMID: 26512132.

68. Baars JE, Kuipers EJ, van Haastert M, Nicolaï JJ, Poen AC, van der Woude CJ. 2012; Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey. J Gastroenterol. 47:1308–1322. DOI: 10.1007/s00535-012-0603-2. PMID: 22627504. PMCID: PMC3523115.